iSpecimen gets Nasdaq compliance extension
Rhea-AI Filing Summary
iSpecimen Inc. (ISPC) received notice on September 8, 2026 that Nasdaq has granted an extension to regain compliance with Nasdaq Listing Rule 5550(b), which requires either $2,500,000 in stockholders’ equity, $35,000,000 in market value of listed securities, or $500,000 in net income from continuing operations. iSpecimen’s plan includes a private placement that closed on May 11, 2026 with approximately $2.5 million in gross proceeds and a planned best-efforts public offering of approximately $5 million in gross proceeds, along with projections indicating stockholders’ equity of about $5.1 million through June 30, 2027. Based on these submissions, Nasdaq extended the company’s deadline to evidence compliance to November 25, 2026, after which failure to demonstrate compliance in required public reports, including the report for the year ended December 31, 2026, could result in delisting, though the current deficiency notice has no immediate effect on trading.
Positive
- None.
Negative
- iSpecimen faces a risk of Nasdaq delisting if it cannot demonstrate compliance with the $2.5 million stockholders’ equity requirement by November 25, 2026 and in its Form 10-K for the year ended December 31, 2026.
Filing Explained
iSpecimen has more time—not confirmed compliance—to address the equity listing deficiency: by
8-K Event Classification
Item 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
1 item
Item 3.01
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Securities
The company received a delisting notice, failed to satisfy a continued-listing rule or standard, or transferred its listing.
Key Figures
Minimum stockholders’ equity requirement: $2,500,000
Alternative market value of listed securities threshold: $35,000,000
Alternative net income requirement: $500,000
+4 more
7 metrics
Minimum stockholders’ equity requirement
$2,500,000
Threshold under Nasdaq Listing Rule 5550(b) for continued listing
Alternative market value of listed securities threshold
$35,000,000
Alternative criterion under Nasdaq Listing Rule 5550(b)
Alternative net income requirement
$500,000
Net income from continuing operations alternative under Nasdaq Listing Rule 5550(b)
Private placement gross proceeds
$2,500,000
Approximate gross proceeds from private placement closed on May 11, 2026
Planned public offering size
$5,000,000
Approximate gross proceeds targeted in planned best-efforts public offering
Projected stockholders’ equity
$5,100,000
Projected stockholders’ equity through June 30, 2027 in company’s submission
Nasdaq compliance extension deadline
November 25, 2026
Date by which iSpecimen must evidence compliance with Listing Rule 5550(b)
Key Terms
Nasdaq Listing Rule 5550(b), stockholders’ equity, market value of listed securities, best-efforts public offering, +2 more
6 terms
Nasdaq Listing Rule 5550(b) regulatory
"granted an extension of time to regain compliance with Nasdaq Listing Rule 5550(b)"
A Nasdaq listing rule that requires companies on the Nasdaq Capital Market to keep their share price at or above a minimum level (commonly $1.00 per share) to avoid delisting. It matters to investors because dropping below that threshold can start a formal review that may remove a stock from the exchange, which can reduce trading liquidity, make shares harder to sell, and hurt a company’s ability to raise capital — similar to a store losing its grade and being forced to close or move to a less prominent location.
stockholders’ equity financial
"The Rule requires listed companies to maintain a minimum of $2,500,000 in stockholders’ equity"
Stockholders’ equity is the portion of a company’s value that belongs to its owners after subtracting what the company owes from what it owns — like the equity in a house after paying the mortgage. For investors it shows the company’s net worth and can indicate financial strength, a cushion against losses, and the amount potentially available to support dividends or reinvestment; tracking changes helps assess whether the business is building or eroding owner value.
market value of listed securities financial
"or alternatively $35,000,000 in market value of listed securities"
Market value of listed securities is the market value of the shares a company has listed on an exchange, calculated as the closing bid price multiplied by the number of listed shares. Exchanges use it as a continued-listing standard, so a company that stays under the required minimum receives a deficiency notice and is given a set period to recover before facing delisting.
best-efforts public offering financial
"and a planned best-efforts public offering of approximately $5 million in gross proceeds"
A best-efforts public offering is when an investment bank or broker agrees to act as a salesperson for a company’s new stock or bond sale but does not promise to buy any unsold shares. Think of it like a consignment sale: the seller provides the goods and the agent tries to find buyers, and the final amount raised depends on demand. For investors this signals that market interest and pricing are uncertain and the company may raise less capital than planned.
pro forma adjustments financial
"a balance sheet no older than 60 days with pro forma adjustments for any significant transaction"
forward-looking statements regulatory
"contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act"
Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.
FAQ
Why did iSpecimen Inc. (ISPC) receive a Nasdaq deficiency notice?
iSpecimen received notice for not meeting Nasdaq Listing Rule 5550(b), which requires at least $2,500,000 in stockholders’ equity, or $35,000,000 in market value of listed securities, or $500,000 in net income from continuing operations.
What extension did Nasdaq grant to iSpecimen Inc. (ISPC)?
Nasdaq granted iSpecimen an extension until November 25, 2026 to evidence compliance with Listing Rule 5550(b), based on its submitted plans and projections to restore stockholders’ equity above the required threshold.
How does iSpecimen Inc. (ISPC) plan to regain Nasdaq compliance?
The plan includes a private placement that closed on May 11, 2026 generating approximately $2.5 million in gross proceeds, a planned best-efforts public offering of about $5 million, and projections of $5.1 million in stockholders’ equity through June 30, 2027.
What happens if iSpecimen Inc. (ISPC) cannot show compliance by the deadlines?
If iSpecimen does not evidence compliance by November 25, 2026 and in its periodic report for the year ended December 31, 2026, Nasdaq staff may move to delist the company’s securities, though iSpecimen could appeal to a Hearings Panel.
Does the Nasdaq deficiency letter immediately affect ISPC stock trading?
No. The company states that the Deficiency Letter has no immediate effect on the listing or trading of its common stock on the Nasdaq Capital Market while it works within the extension period to regain compliance.
AI-generated analysis. How Rhea-AI works. Not financial advice.
